World's Best Scientists 2026 revealed!

D-Index & Metrics

Psychology

D-Index
66
Citations
22703
World Ranking
2664
National Ranking
112

Overview

Rolf R. Engel is affiliated with Ludwig-Maximilians-Universität München in Germany, focusing on research primarily in the fields of medicine and psychology. Their work spans multiple subfields including psychiatry and mental health, clinical psychology, cognitive neuroscience, pharmacology, and experimental and cognitive psychology.

Engel's notable research topics cover schizophrenia research and treatment, functional brain connectivity studies, treatment of major depression, bipolar disorder and its treatment, mental health research topics broadly, obsessive-compulsive spectrum disorders, and electroconvulsive therapy studies.

Frequent publication venues for Engel include Brain Sciences, with three publications, European Archives of Psychiatry and Clinical Neuroscience and The World Journal of Biological Psychiatry, each with two publications. Additional venues include JAMA Psychiatry and The Lancet Psychiatry.

Among recent papers authored or co-authored by Engel are:

  • Neurocognitive deficits in depression: a systematic review of cognitive impairment in the acute and remitted state, 2022, European Archives of Psychiatry and Clinical Neuroscience
  • Antipsychotic Drugs and Cognitive Function, 2024, JAMA Psychiatry
  • Sex differences in pharmacological treatment of major depressive disorder: results from the AMSP pharmacovigilance program from 2001 to 2017, 2021, Journal of Neural Transmission
  • Time trends in pharmacological treatment of major depressive disorder: Results from the AMSP Pharmacovigilance Program from 2001-2017, 2020, Journal of Affective Disorders
  • Neurocognitive Deficits in First-Episode and Chronic Psychotic Disorders: A Systematic Review from 2009 to 2022, 2023, Brain Sciences

Engel frequently collaborates with several co-authors including Johanna Seifert, Susanne Stübner, Sermin Toto, R. Grohmann, and Spyridon Siafis, each contributing multiple joint publications.

Best Publications

  • Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

    Stefan Leucht;Andrea Cipriani;Andrea Cipriani;Loukia Spineli;Dimitris Mavridis

  • Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

    Stefan Leucht;Caroline Corves;Caroline Corves;Dieter Arbter;Rolf R Engel

  • What does the PANSS mean

    Stefan Leucht;Stefan Leucht;John M. Kane;Werner Kissling;Johannes Hamann

  • The Effect of Family Interventions on Relapse and Rehospitalization in Schizophrenia—A Meta-analysis

    Gabi Pitschel-Walz;Stefan Leucht;Josef Bäuml;Werner Kissling

  • Clinical implications of Brief Psychiatric Rating Scale scores.

    Stefan Leucht;John M. Kane;Werner Kissling;Johannes Hamann

  • Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

    Stefan Leucht;Thomas R.E. Barnes;Werner Kissling;Rolf R. Engel

  • How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials.

    S Leucht;D Arbter;R R Engel;W Kissling

  • Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia.

    Norbert Müller;Michael Riedel;Constanze Scheppach;Bernd Brandstätter

  • Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.

    Stefan Leucht;Gabi Pitschel-Walz;Rolf R. Engel;Werner Kissling

  • Lithium versus carbamazepine in the maintenance treatment of bipolar disorders - a randomised study

    W. Greil;W. Ludwig-Mayerhofer;N. Erazo;C. Schöchlin

  • Linking the PANSS, BPRS, and CGI: Clinical Implications

    Stefan Leucht;John M Kane;Eva Etschel;Werner Kissling

  • CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects.

    K. Buerger;S. J. Teipel;Ray Zinkowski;K. Blennow

  • Definitions of response and remission in schizophrenia: recommendations for their use and their presentation

    S. Leucht;J. M. Davis;R. R. Engel;W. Kissling

  • Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis

    Bartosz Helfer;Myrto T. Samara;Maximilian Huhn;Elisabeth Klupp

  • Psychoeducation and compliance in the treatment of schizophrenia: results of the Munich Psychosis Information Project Study.

    Gabriele Pitschel-Walz;Josef Bäuml;Wolfram Bender;Rolf R. Engel

  • The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia.

    Brigitta Bondy;Michael Spaeth;Martin Offenbaecher;Karin Glatzeder

  • What does the HAMD mean

    Stefan Leucht;Hein Fennema;Rolf Engel;Marion Kaspers-Janssen

  • Is the Superior Efficacy of New Generation Antipsychotics an Artifact of LOCF

    Stefan Leucht;Rolf R. Engel;Josef Bäuml;John M. Davis

  • Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs.

    Stefan Leucht;John M Davis;Rolf R Engel;John M Kane

  • Reduced hippocampal volumes associated with the long variant of the serotonin transporter polymorphism in major depression.

    Thomas Frodl;Eva M. Meisenzahl;Peter Zill;Thomas Baghai

  • Second-generation versus first-generation antipsychotic drugs for schizophrenia : a meta-analysis. Commentary

    Peter Tyrer;Tim Kendall;Stefan Leucht;Caroline Corves

Frequent Co-Authors

H.-J. Möller
H.-J. Möller Ludwig-Maximilians-Universität München
Norbert Kathmann
Norbert Kathmann Humboldt-Universität zu Berlin
Peter Zwanzger
Peter Zwanzger Ludwig-Maximilians-Universität München
Margot Albus
Margot Albus Ludwig-Maximilians-Universität München
Frank Padberg
Frank Padberg Ludwig-Maximilians-Universität München
Jules Angst
Jules Angst University of Zurich
Armin Szegedi
Armin Szegedi MSD (United States)
Ronald Bottlender
Ronald Bottlender Ludwig-Maximilians-Universität München
Paul Allen
Paul Allen Royal Holloway University of London
M. Katherine Shear
M. Katherine Shear Columbia University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a degree in psychology opens doors to a variety of rewarding online programs and career pathways. Many students opt for online bachelor’s or master’s degrees in psychology, counseling, or clinical mental health to balance flexibility with academic rigor. These programs often meet the academic groundwork required for advanced roles, such as becoming a licensed therapist.

Requirements for licensure can differ across states and cities. For instance, those interested in practicing in Massachusetts should review the licensed therapist requirements in Boston. Aspiring counselors in New York should look into how to become a licensed therapist in Buffalo. Similarly, those aiming to work as therapists in Arizona or North Carolina should consider the specific Chandler licensed therapist requirements or Charlotte licensed therapist requirements.

With a rise in demand for mental health professionals, online degrees offer a direct pathway to key qualifications and career advancement in diverse regions across the USA.

Best Scientists Citing Rolf R. Engel

Trending Scientists

Recently Published Articles